Taken together, our results implied that the identified differential metabolites, particularly 1-methyladenosine, 9,10-DHOME, acetylcholine chloride, dodecanedioic acid, GMP, and N6-acetyl-L-lysine, may be candidate biomarkers for CHD, as well as mTOR signaling pathway, sphingolipid signaling pathway, FoxO signaling pathway, TCA cycle, AMPK signaling pathway, HIF-1 signaling pathway and cGMP-PKG signaling pathway may play crucial roles in CHD occurrence and progression. The gene discussed is MTOR; the disease is coronary artery disorder.